Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

3.32AUD
27 Apr 2017
Change (% chg)

$0.04 (+1.22%)
Prev Close
$3.28
Open
$3.30
Day's High
$3.44
Day's Low
$3.30
Volume
2,158,135
Avg. Vol
740,719
52-wk High
$3.44
52-wk Low
$1.01

MSB.AX

Chart for MSB.AX

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $1,403.67
Shares Outstanding(Mil.): 427.95
Dividend: --
Yield (%): --

Financials

  MSB.AX Industry Sector
P/E (TTM): -- 57.64 30.27
EPS (TTM): -0.03 -- --
ROI: -1.23 0.35 13.24
ROE: -1.69 6.20 14.40

BRIEF-Mesoblast receives A$3.7m from Australian Government for research and development

* Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX Source text for Eikon: Further company coverage:

Apr 05 2017

BRIEF-FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy

* FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy to grow heart muscle in children with congenital heart disease Source text for Eikon: Further company coverage:

Apr 03 2017

BRIEF-IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial

* Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast’S phase 3 chronic heart failure trial

Mar 31 2017

BRIEF-Mesoblast updates on durable three year outcomes in disc disease

* Mesoblast says 36-month results from randomized, placebo-controlled 100- patient phase 2 trial of allogeneic mpcs in patients with chronic low back pain

Mar 14 2017

BRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

* FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

Mar 07 2017

BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV

* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents

Feb 15 2017

BRIEF-Mesoblast qtrly loss per share 5.24 cents

* Mesoblast provides corporate update and financial results for the first quarter ended September 30, 2016 Source text for Eikon: Further company coverage:

Nov 14 2016

More From Around the Web

Earnings vs. Estimates